Anticomplement Treatment in Atypical and Typical Hemolytic Uremic Syndrome

被引:34
|
作者
Fakhouri, Fadi [1 ,2 ]
Loirat, Chantal [3 ]
机构
[1] Univ Nantes, INSERM, Ctr Rech Transplantat & Immunol, Dept Nephrol,UMR 1064, Nantes, France
[2] CHU Nantes, Nantes, France
[3] Sorbonne Paris Cite, Univ Paris Diderot, Hop Univ Robert Debre, AP HP,Dept Pediat Nephrol, Paris, France
关键词
MONITORING ECULIZUMAB TREATMENT; INVASIVE MENINGOCOCCAL DISEASE; COMPLEMENT FUNCTIONAL TESTS; FACTOR-H AUTOANTIBODY; THROMBOTIC MICROANGIOPATHY; PEDIATRIC-PATIENTS; FOLLOW-UP; ACTIVATION; OUTCOMES; THERAPY;
D O I
10.1053/j.seminhematol.2018.04.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The dissection of the pathogenic mechanisms of the various forms of the hemolytic uremic syndrome (HUS) has paved the way for the design of specific efficacious treatments. Such mechanistic approach led to a revolution in the management of atypical HUS with the use of the first-in class C5 blocker, eculizumab. The availability of this anticomplement drug has also raised unsettled questions regarding the cost or burden and optimal duration of therapy and its use in secondary HUS. The efficacy of eculizumab in Shiga toxin producing Escherichia coli-associated HUS is not to date established and the results of ongoing prospective studies are eagerly awaited. Nevertheless, the emergence of anticomplement therapies (eculizumab and other drugs in development) has transformed our approach of HUS. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:150 / 158
页数:9
相关论文
共 50 条
  • [21] Atypical Hemolytic Uremic Syndrome
    Kavanagh, David
    Goodship, Tim H.
    Richards, Anna
    SEMINARS IN NEPHROLOGY, 2013, 33 (06) : 508 - 530
  • [22] Atypical hemolytic uremic syndrome
    Yoshida Y.
    Kato H.
    Nangaku M.
    Renal Replacement Therapy, 3 (1)
  • [23] Atypical hemolytic uremic syndrome
    Sepulveda, Rodrigo A.
    Tagle, Rodrigo
    Jara, Aquiles
    REVISTA MEDICA DE CHILE, 2018, 146 (06) : 770 - 779
  • [24] THE SUCCESSFUL TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME WITH PLASMAPHERESIS
    ROBSON, WLM
    LEUNG, AKC
    CLINICAL NEPHROLOGY, 1991, 35 (03) : 119 - 122
  • [26] SUCCESS OF ECULIZUMAB IN THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME
    Kantar, Asli
    Gulleroglu, Kaan
    Bayrakci, Umut
    Ozkaya, Ozan
    Ozcan, Ebru
    Baskin, Esra
    PEDIATRIC NEPHROLOGY, 2013, 28 (08) : 1572 - 1572
  • [27] The Importance of Eculizumab in the Treatment of Atypical Hemolytic Uremic Syndrome
    Santos, Mariana S.
    Ventura, Sofia
    Alves, Abel
    Cabral, Raquel
    Henriques, Manuela
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [28] Monitoring and modeling treatment of atypical hemolytic uremic syndrome
    Heinen, Stefan
    Pluthero, Fred G.
    van Eimeren, Viola F.
    Quaggin, Susan E.
    Licht, Christoph
    MOLECULAR IMMUNOLOGY, 2013, 54 (01) : 84 - 88
  • [29] Atypical hemolytic uremic syndrome: from diagnosis to treatment
    Franchini, Massimo
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2015, 53 (11) : 1679 - 1688
  • [30] Pharmacological treatment of atypical hemolytic-uremic syndrome
    Vester, Udo
    Mache, Christoph J.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (02): : 123 - 135